The safety of vedolizumab for ulcerative colitis and Crohn's disease.
about
The safety of vedolizumab for the treatment of ulcerative colitis.Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Combination therapy for inflammatory bowel diseaseNew choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.Progress in the treatment and outcome of pediatric inflammatory bowel disease patients.Second Korean guidelines for the management of ulcerative colitis.Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects.New treatment strategies for ulcerative colitis.Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions.Unintended Immunological Consequences of Biologic Therapy.Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.Emerging biologics in inflammatory bowel disease.The biologics of ulcerative colitis.Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.Long-term Efficacy of Vedolizumab for Ulcerative Colitis.Long-term Efficacy of Vedolizumab for Crohn's Disease.Infection risk with biologic therapy in patients with inflammatory bowel disease.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review.Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.A rare case of Crohn's ileitis in a patient with constitutional mismatch repair deficiencyPerioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy.Proteinase 3-antineutrophil cytoplasmic antibody-positive ulcerative colitis presenting with abducens neuropathyThe expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Disseminated Nocardiosis Associated with Treatment with Infliximab in a Patient with Ulcerative Colitis.Novel treatments for inflammatory bowel disease.Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum?Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
P2860
Q30235363-60C8E528-2560-4301-BB24-3D61183A4995Q30235523-AB6B413F-2C8C-4A60-9E87-074E076C6D1DQ30235581-32C50891-5421-4152-8CE6-BA22754B7DC3Q33607108-2F4B0015-7DAB-4092-A9E3-8919CC79A16DQ33646452-8C44A70E-38CA-4795-BA28-282238A17A34Q35962448-DDA71A02-4B16-421D-B4BB-451F65F0122DQ36056969-0CBF254F-28E1-4595-A3E2-303AA7452DFBQ37662503-9DF0DCC0-4A9B-46F5-A405-2BF530AB6366Q37691599-87617A99-2B71-486A-9BB3-92597AB36E8BQ38643163-0CF1BACF-2495-44D5-B442-1026B31421FBQ38670811-41FF462B-B92F-4895-AB05-2610AA9B708AQ38735146-3CE01AEB-5FCF-41F5-8FF1-E4A26C4E9EE0Q38768891-CF4E74ED-E629-45BC-A126-743BEFFFD1D3Q38871098-F5AEA83D-4B3D-4A0D-AE0C-ADBD7FE5540EQ38974524-6A25E89C-ABF3-43E3-931F-2EDC89A6844CQ39004625-9C6E6678-A538-44AA-8496-4186A0CF04ECQ39037681-6815F68F-3019-4A99-8975-0A73E28D5B3DQ39251794-604CECA6-C4AF-477E-9807-F8DC129C9ED7Q39317326-2089297A-38A3-41CF-A03E-8BFF9641A94FQ39340717-507005AF-2E4E-432C-A67C-D05D601DF6CAQ39340730-53CFA697-1A27-40AD-B436-6FBC863DB336Q39429997-5E1C0DC2-D521-43EB-B210-9CF6EA5D0C63Q39435409-322CF768-2A0D-4FBD-8064-7F8AA450065AQ40100993-C0A1D05A-B5CE-477A-B62D-0EB75A0F1134Q40378196-84BE0E4D-52CF-4FA3-959D-6B70F68B7D44Q40496228-C9DA9A77-16A3-4E06-B717-99928341A13AQ41820439-1F90B874-DE3B-46F8-8F6D-09F6F05A0373Q41990775-C0842AF0-8464-442F-9256-99DC7667153AQ42264454-B6EFCB1A-483F-474A-9DC2-F82C4D0852E9Q44581309-369DD6AD-5648-446E-B758-C02C0C4AD796Q46103014-D9C494EA-52BF-45D6-83A3-6B8A0D11E782Q47109861-0EE8D0B1-67AA-4C23-BF20-E6CE41089854Q47152246-C8E38A39-4754-4982-A174-F6602B616E58Q47563211-522BBF7F-8974-4DC1-8AD8-61D7B1C38F28Q48102910-941525FE-A057-4BE1-9DFD-004A4609E758Q48151874-499D9B9C-65D0-4119-998E-87EB017F844AQ48308809-DBCAF611-A818-42FB-BB2C-37A6D9232AD0Q48334536-5B72DCF8-7306-4DE0-BA5D-BE2293856093Q50132200-4D89ACA7-5553-40C6-B2E1-D8C35CA7FF93Q50764332-E03C39D8-BE93-4742-A668-FF10A93B2F0B
P2860
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
@en
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
@nl
type
label
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
@en
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
@nl
prefLabel
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
@en
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
@nl
P2093
P2860
P50
P1433
P1476
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
@en
P2093
Asit Parikh
Brihad Abhyankar
Bruce E Sands
Catherine Milch
Geert D'Haens
Irving Fox
Remo Panaccione
Serap Sankoh
Silvio Danese
William Sandborn
P2860
P304
P356
10.1136/GUTJNL-2015-311079
P407
P577
2016-02-18T00:00:00Z